GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stemline Therapeutics Inc (NAS:STML) » Definitions » Unpaid Loss & Loss Reserve

Stemline Therapeutics (Stemline Therapeutics) Unpaid Loss & Loss Reserve


View and export this data going back to 2013. Start your Free Trial

What is Stemline Therapeutics Unpaid Loss & Loss Reserve?

Unpaid Loss & Loss Reserve only applies to insurance companies.


Stemline Therapeutics (Stemline Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an immunotherapy). The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.
Executives
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Kenneth Hoberman officer: Chief Operating Officer 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Alan S Forman director 55 WHITNEY AVENUE, 5TH FLOOR, NEW HAVEN CT 06511
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Eric K Rowinsky officer: Chief Medical Officer IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014